Karyopharm Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	37.67	62.48	52.23	135.19	190.46	85.92
Short-Term Investments	8.21	46.24	139.21	142.78	38.16	163.32
Cash & Short-Term Investments	45.88	108.71	191.44	277.97	228.62	249.24
Cash Growth	-65.64%	-43.21%	-31.13%	21.59%	-8.28%	-4.85%
Receivables	31.88	30.77	27.96	54.89	23.9	12.88
Inventory	3.97	4.74	3.04	4.22	4.11	2.64
Prepaid Expenses	8.03	12.25	10.81	12.02	12.64	9.29
Restricted Cash	-	0.03	0.66	1.06	6.35	2.48
Total Current Assets	89.75	156.49	233.92	350.16	275.61	276.53
Property, Plant & Equipment	4.8	6.28	4.88	7.38	9.56	11.58
Long-Term Investments	-	-	-	-	-	24.22
Long-Term Accounts Receivable	-	-	-	-	19.51	-
Other Long-Term Assets	1.68	1.64	1.64	0.63	0.64	0.72
Total Assets	96.23	164.42	240.44	358.17	305.31	313.05
Accounts Payable	5.39	5.11	3.12	2.77	1.6	4.45
Accrued Expenses	66.33	60.65	61.39	58.42	69.12	52.93
Short-Term Debt	12.75	24.43	-	-	-	-
Current Portion of Leases	0.92	0.44	3.31	2.87	2.32	1.92
Current Unearned Revenue	-	-	-	-	-	0.3
Other Current Liabilities	1.77	1.64	1.65	1.85	0.68	0.61
Total Current Liabilities	87.16	92.26	69.48	65.91	73.72	60.2
Long-Term Debt	250.24	236.45	303.4	302.82	302.29	191.02
Long-Term Leases	6.01	6.71	2.79	6.1	8.97	11.29
Other Long-Term Liabilities	22.08	15.01	0.98	-	-	-
Total Liabilities	365.49	350.44	376.64	374.83	384.98	262.5
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,388	1,378	1,351	1,328	1,099	1,120
Retained Earnings	-1,657	-1,563	-1,487	-1,344	-1,179	-1,070
Comprehensive Income & Other	-0.26	-0.36	-0.16	-0.64	0.19	0.52
Shareholders' Equity	-269.26	-186.02	-136.21	-16.66	-79.67	50.55
Total Liabilities & Equity	96.23	164.42	240.44	358.17	305.31	313.05
Total Debt	269.92	268.02	309.5	311.79	313.58	204.22
Net Cash (Debt)	-224.05	-159.31	-118.05	-33.83	-84.96	45.02
Net Cash Growth	-	-	-	-	-	-29.28%
Net Cash Per Share	-26.24	-18.84	-15.50	-6.20	-16.94	9.37
Filing Date Shares Outstanding	17.05	8.42	7.67	7.56	5.28	4.98
Total Common Shares Outstanding	8.7	8.41	7.66	7.55	5.05	4.93
Working Capital	2.59	64.23	164.44	284.25	201.89	216.33
Book Value Per Share	-30.94	-22.11	-17.78	-2.21	-15.78	10.26
Tangible Book Value	-269.26	-186.02	-136.21	-16.66	-79.67	50.55
Tangible Book Value Per Share	-30.94	-22.11	-17.78	-2.21	-15.78	10.26
Machinery	-	2.21	2.29	2.33	2.25	1.97
Leasehold Improvements	-	4.88	4.88	5.45	5.45	5.44

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q